In the United States, the past 15 years have seen continued growth in the use of peritoneal dialysis (PD) as a kidney replacement therapy driven largely by policy and payment reforms such as the End-Stage Renal Disease Prospective Payment System and the Advancing American Kidney Health Initiative.1,2 PD offers several potential benefits over in-center hemodialysis (ICHD), including greater treatment autonomy, greater quality of life,3 and, more recently, reduced risks of COVID-19 by avoiding dialysis in congregate health care settings.